Deep PSA response and extended time‐to‐nadir as robust predictors of survival in Asian patients with de novo metastatic hormone‐sensitive prostate cancer receiving upfront intensified treatment

Introduction In de novo metastatic hormone‐sensitive prostate cancer (mHSPC) treated with upfront intensification using androgen receptor signaling inhibitor or chemotherapy (Docetaxel), achieving a PSA nadir less than 0.2 ng/mL, indicative of superior survival in trials, may often be unattainable i...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Prostate 2025-01, Vol.85 (1), p.30-39
Hauptverfasser:	Wong, Chris H.‐M., Ko, Ivan C.‐H., Leung, David K.‐W., Siu, Brian, Cheng, Cheuk‐K. K., Lim, Yung‐Y. J., Mok, Hiu T., Kwok, Chun‐F. B., Tang, Cheuk Y., Leung, Steven C.‐H., Chiu, Peter K.‐F., Teoh, Jeremy Y.‐C., Ng, Chi F.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Androgen Receptor Antagonists - therapeutic use androgen receptor signaling inhibitor Androgen receptors Asian patients Asian People Chemotherapy Clinical trials docetaxel Docetaxel - therapeutic use Hong Kong - epidemiology Humans Male Metastases Metastasis metastatic hormone‐sensitive prostate cancer Middle Aged Neoplasm Metastasis Original Prospective Studies Prostate cancer Prostate-Specific Antigen - blood Prostatic Neoplasms - blood Prostatic Neoplasms - drug therapy Prostatic Neoplasms - mortality Prostatic Neoplasms - pathology PSA kinetics Regression analysis Survival Treatment Outcome upfront intensified treatment
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!